Verstovsek Verstovsek S S Passamonti Passamonti F F Rambaldi Rambaldi A A A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea Cancer Cancer 2014 2014 120 120 513 513 520 520 10.1002/cncr.28441 10.1002/cncr.28441 24258498 24258498. Here, JAK1 is linked to acquired polycythemia vera.